Explore / Clinical trial
Clinical trial

Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression

Joshua RosenblatEnrolling by invitationStarted Jul 1, 202665 enrolledCanadaNCT07737990

Abstract

Psilocybin-assisted psychotherapy requires a lot of resources, with more psychotherapy being provided to integrate the meanings and insights derived from the psilocybin dosing sessions. If group integration therapy is beneficial, then it has the potential to reduce resources required per patient for psilocybin-assisted psychotherapy, thereby increasing the cost-effectiveness of the treatment. However, no research has been done to understand if and how group therapy can support psychedelic integration for people with mood disorders. Therefore, the purpose of this study is to explore the benefit of psilocybin-assisted group therapy and to determine if psychedelic group integration therapy is acceptable to people who have received psychedelic-assisted therapy for mood disorders.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinDepression

Keywords

Treatment-resistant Depression (TRD)

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

This study's objects

Directly linked records, matched by DOI, trial reference, or registry, not just topic.

Publications from this trial

ArticlePsilocybin

Psychedelic-Assisted Group Therapy: A Systematic Review.

Trope A, Anderson BT, Hooker AR +3

Europe PMC2019
ArticlePsilocybin

Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research.

Tai SJ, Nielson EM, Lennard-Jones M +7

Europe PMC2021
ArticlePsilocybin

Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice.

Gorman I, Nielson EM, Molinar A +2

Europe PMC2021
ArticlePsilocybin

The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences.

Frymann T, Whitney S, Yaden DB +1

Europe PMC2022
ArticlePsilocybin

Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review.

Ko K, Knight G, Rucker JJ +1

Europe PMC2022
ArticlePsilocybin

Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies.

Perez N, Langlest F, Mallet L +9

Europe PMC2023
ArticleKetamine

Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions.

McIntyre RS, Alsuwaidan M, Baune BT +24

Europe PMC2023
ArticlePsychedelics

How psychedelic-assisted therapy works for depression: expert views and practical implications from an exploratory Delphi study.

Johansen L, Liknaitzky P, Nedeljkovic M +1

Europe PMC2023
ArticlePsilocybin

Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.

Haikazian S, Chen-Li DCJ, Johnson DE +6

Europe PMC2023
ArticlePsilocybin

Group psychedelic therapy: empirical estimates of cost-savings and improved access.

Marseille E, Stauffer CS, Agrawal M +5

Europe PMC2023
ArticlePsilocybin

A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review.

Wong S, Kwan ATH, Teopiz KM +8

Europe PMC2024
ArticlePsilocybin

Development and psychometric validation of a novel scale for measuring 'psychedelic preparedness'.

McAlpine RG, Blackburne G, Kamboj SK

Europe PMC2024